Danco Laboratories

What Danco Laboratories does

Danco Laboratories, LLC is a privately held pharmaceutical company that manufactures and distributes Mifeprex (mifepristone), the FDA-approved brand-name medication used in combination with misoprostol for medical termination of early intrauterine pregnancy through 70 days gestation. The company received FDA approval on September 28, 2000 and operates under the Mifepristone REMS Program, a restricted distribution framework requiring prescriber and pharmacy certification, patient agreement execution, and dispensing only through certified settings. Mifeprex is the company's sole product, has been used by over 5–6 million U.S. patients since launch, and accounts for roughly 60–65% of all U.S. abortions per third-party sources.

The underlying technology is a 200mg oral mifepristone tablet, a synthetic steroid that acts as a progesterone-receptor antagonist, administered as a single dose followed 24–48 hours later by 800mcg buccal misoprostol to induce uterine contractions and pregnancy expulsion. Danco's business model is single-stream pharmaceutical product sales with no disclosed services, licensing, or alternative revenue lines; pricing is not publicly disclosed, and reimbursement flows through commercial insurance and variable state Medicaid programs using codes such as S0190. Distribution is purely domestic and runs through certified OB/GYNs and family physicians, certified pharmacies (CVS Pharmacy in 22 states, Walgreens, Denver Health, Pavilion Pharmacy at UC Davis), and provider networks including Planned Parenthood and the National Abortion Federation; the January 2023 FDA REMS modification also enabled telehealth prescribing and mail-order dispensing, which the company is actively defending in litigation through 2026.

The company is reportedly incorporated in the Cayman Islands with operational headquarters in New York and maintains a deliberately opaque corporate and ownership structure. It has been the subject of congressional scrutiny, including a DOJ investigation request from Senator Josh Hawley, and has engaged Arnold & Porter and Democracy Forward Foundation as core legal counsel to defend FDA's mifepristone regulations in multiple state-level lawsuits. The brand identity is marketed under the 'Early Option Pill' consumer-facing label.

Name

Danco Laboratories

Legal name

Danco Laboratories, LLC

Website

https://earlyoptionpill.com

Company type

Private

Founded year

2000

Operating status

Operating

Short description

Danco Laboratories is a privately held U.S. pharmaceutical company that manufactures and distributes Mifeprex (mifepristone), the FDA-approved brand-name medication abortion drug, serving certified prescribers, certified pharmacies including CVS and Walgreens, and millions of U.S. patients since 2000.

Ownership category

akta.pro rank

Product category

Medication Abortion Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAJ

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Pharmaceutical manufacturing
• Medication abortion
• Reproductive health drugs
• Prescription pharmaceuticals
• FDA-approved therapeutics

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Danco generates revenue from sales of its brand-name Mifeprex (mifepristone) to healthcare providers, clinics, hospitals, and certified pharmacies. The company is described as having Mifeprex as its only product. Revenue is derived from direct product sales with no alternative revenue streams mentioned.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Danco Laboratories manufactures and distributes Mifeprex (mifepristone), the only FDA-approved brand-name version of the abortion pill in the United States. The 200mg oral tablet is used in a two-drug regimen with misoprostol to medically terminate intrauterine pregnancy through 70 days (10 weeks) gestation. The product is sold exclusively through the FDA-mandated Mifepristone REMS Program to certified prescribers and certified pharmacies.

Product overview

Danco Laboratories is a single-product pharmaceutical company specializing in reproductive health. The company's sole product is Mifeprex (mifepristone), an FDA-approved abortion medication used since 2000. Mifeprex is used in a regimen with misoprostol and is available through certified healthcare providers and certified pharmacies. The company also provides patient education materials, prescriber resources, and state-specific insurance/reimbursement information through its website.

Differentiator

Problem solved

Functional benefit

Brands

• Mifeprex: Brand name for mifepristone, FDA-approved since 2000 for medical termination of early pregnancy up to 70 days gestation, used in combination with misoprostol.

Products and services

• Mifeprex (mifepristone) FDA-approved 200mg oral mifepristone tablet used in combination with misoprostol for medical termination of intrauterine pregnancy through 70 days (10 weeks) gestation. Distributed exclusively through the Mifepristone REMS Program to certified prescribers and certified pharmacies for use by women seeking early pregnancy termination.

Quantifiable outcome

• 93-98% effective for safely ending early pregnancy; 2-7% of women will need a surgical procedure
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Democracy Forward FoundationcoreImplementation/ SI/ Consulting PartnerLegal representation for Danco Laboratories in lawsuits challenging FDA regulation of mifepristone. The foundation filed motions on behalf of Danco to intervene in lawsuits brought by Republican attorneys general of Louisiana, Idaho, and Missouri seeking to block telehealth abortion and pharmacy dispensing of mifepristone.
• Arnold & PortercoreImplementation/ SI/ Consulting PartnerLegal counsel representing Danco Laboratories in defense of FDA mifepristone regulations. Working alongside Democracy Forward Foundation to defend the manufacturer's position in ongoing litigation.
• National Abortion Federation (NAF)majorChannel Partner/ Reseller/ DistributorNAF hotline (1-800-772-9100) refers patients to certified Mifeprex providers. Danco's website lists NAF as a resource for locating healthcare providers who offer Mifeprex.
• Planned Parenthood Federation of AmericamajorChannel Partner/ Reseller/ DistributorMany Planned Parenthood health centers offer Mifeprex for early pregnancy termination. Referenced on Danco's website as a resource for patients seeking Mifeprex providers (1-800-230-PLAN).
• CVS PharmacymajorChannel Partner/ Reseller/ DistributorCertified pharmacy dispensing Mifeprex in 22 states: CA, CO, CT, DC, DE, HI, IL, MA, MD, ME, MI, MN, NH, NJ, NV, NM, NY, OR, PA, RI, VA, VT, WA. One of the major retail pharmacy chains distributing Mifeprex under the REMS Program.
• WalgreensmajorChannel Partner/ Reseller/ DistributorCertified pharmacy dispensing Mifeprex in multiple states. Listed on Danco's website as a certified pharmacy partner for Mifeprex distribution.
• Abortion.com, Abortion Clinics Online, Abortion Finder, Plan C, I Need An AminorChannel Partner/ Reseller/ DistributorThird-party websites referenced on Danco's website as resources for locating Mifeprex providers. These platforms help patients find certified prescribers and pharmacies offering medication abortion.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Organon: Organon is a global women's health pharmaceutical company spun off from Merck, with a portfolio spanning contraception, fertility, and reproductive health. It is comparable to Danco as a broader women's-health pharmaceutical player, though with significantly more diversification beyond medication abortion.
• Sandoz (Novartis): Sandoz is a major global generic pharmaceutical company with a women's health and reproductive medicine portfolio. It is comparable to Danco as a generic pharmaceutical manufacturer with the regulatory capabilities to enter highly regulated product categories.
• Teva Pharmaceutical Industries: Teva is one of the world's largest generic pharmaceutical manufacturers with a broad portfolio including women's health and reproductive products. It is comparable to Danco as a generic pharmaceutical manufacturer with relevant manufacturing scale and regulatory expertise.
• Bayer (Women's Health / Pharmaceuticals): Bayer operates a large women's health pharmaceutical business including contraception (Mirena, Yaz) and gynecological therapies. It is comparable to Danco as a major pharmaceutical player in adjacent reproductive/women's health therapeutic areas.

Others

• CVS Health: CVS Health operates the largest U.S. retail pharmacy chain and is a certified dispensing partner for Mifeprex in 22 states. It is relevant as a distribution partner rather than a direct competitor, providing the physical retail infrastructure through which Danco's product reaches patients.
• Planned Parenthood Federation of America: Planned Parenthood is one of the largest U.S. providers of medication abortion and a channel partner for Danco. It is comparable to Danco as a participant in the same medication abortion ecosystem, though it operates as a healthcare provider rather than a manufacturer.

Emerging players

• TherapeuticsMD: TherapeuticsMD is a U.S. women's health pharmaceutical company focused on menopause, contraception, and reproductive health products. It is comparable to Danco as a niche women's health pharmaceutical company, though with a different therapeutic focus.
• Linepharma: Linepharma is an international pharmaceutical company focused on mifepristone and misoprostol-based reproductive health products. It is comparable to Danco as a specialized pharmaceutical manufacturer in medication abortion/gynecological indications, though it operates primarily outside the U.S.

Direct peers

• GenBioPro: GenBioPro is the only other U.S. manufacturer of mifepristone, producing the generic version. It is the most directly comparable peer — both companies operate under the same FDA REMS program, partner on litigation, and compete in the identical U.S. medication abortion market.
• Exelgyn: Exelgyn manufactures Mifegyne, the leading international brand of mifepristone, and has been a major mifepristone supplier outside the U.S. The company is directly comparable as another mifepristone-focused pharmaceutical company operating under reproductive health regulatory frameworks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Danco Laboratories